The child that received 31 examinations was an outlier: a 3.5 year old child with TUBA1A mutations causing lissencephaly and infantile spasms managed on vigabatrin from 2009 to 2021, with examinations every 3–6 months over that period. This evidence concerns the gene TUBA1A and lissencephaly spectrum disorders.